He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma (NHL) and other types of leukemia.
VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study
Quick facts: VolitionRx
Price: 3.27 USD
Market Cap: $156.7 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE